Evidence map›Paper›PMID 38380117›Full record

ArticleClinical and translational radiation oncology2024

SABR for oligometastatic renal cell carcinoma.

Chang David, Ali Muhammad, Udovicich Cristian, Tran Ben, Azad Arun, Au Lewis, Spain Lavinia, Perera Marlon, Siva Shankar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chang DavidDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Ali MuhammadDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Udovicich CristianDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Tran BenSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Azad ArunSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Au LewisSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Spain LaviniaSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Perera MarlonDivision of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Siva ShankarDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Peter MacCallum Cancer Centre · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stereotactic ablative body radiotherapy (SABR) aims to accurately deliver a higher than conventional dose of radiotherapy to a well-defined target tumour incorporating advanced immobilisation and imaging techniques. SABR is an emerging treatment option for primary kidney cancer especially when surgery is contraindicated. Increasingly, SABR is being incorporated into the management of low-volume stage IV kidney cancers to delay the need for systemic therapy or to prolong the duration of ongoing systemic treatment. This review will evaluate the evidence and limitations of SABR for oligometastatic renal cell carcinoma.

Indexed as

OligometastasisRenal cell carcinomaStereotactic ablative body radiotherapyStereotactic ablative radiotherapy

Identifiers

PMID38380117
PMCPMC10877104
OpenAlexW4391738183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.